



HPTN at AIDS 2024

22–26 July in Munich, Germany and virtually

Global Village	<p>21 - 25 July • 10:00 a.m. - 4:00 p.m. CEST • Booth HT06 HVTN + HPTN Joint Networking Booth: "Help End HIV: Clinical Trials for HIV Prevention"</p>
Presentations	<p>23 July • 3:00 p.m. - 4:00 p.m. CEST • Room 14b/Channel 3 Oral Abstract Session - <i>Advanced HIV Disease: Hiding in Plain Sight</i></p> <ul style="list-style-type: none">• Performance characteristics of HIV RNA screening with long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) in the multicenter global HIV Prevention Trials Network 083 (HPTN 083) Study <p>25 July • 10:30 a.m. - 11:30 a.m. CEST • Room 13a/Channel 7 Symposium - <i>Use of Long-Acting Injectable Cabotegravir in Pregnant & Lactating People</i></p> <ul style="list-style-type: none">• Safety of injectable cabotegravir in pregnancy: Results from HPTN 084• Pharmacokinetics and dosing requirements for injectable cabotegravir during pregnancy: Results from HPTN 084
Posters	<p>Association between substance use and PrEP adherence among AGYW enrolled in an HIV prevention study (HPTN 082) in Southern Africa</p> <p>Pre-Exposure Prophylaxis product choice of participants in HPTN 083</p> <p>A community-academic partnership to empower Black MSM for economic development, advocacy, and HIV prevention research: HPTN 096</p> <p>Changes in sexual behavior among adolescent girls receiving long-acting injectable cabotegravir for HIV prevention: the HPTN 084-01 study</p> <p>What factors influence whether stigmatizing attitudes change over time? An analysis of HIV stigma attitudes and perceptions among community members participating in the HPTN 071 (PopART) trial</p> <p>HPTN 094: Engaging Key Community Stakeholders in Preparation for Mobile Clinics Providing Integrated Health Services (Medication for Opioid Use Disorder and HIV Treatment/Prevention Services) for People Who Inject Drugs (PWID)</p> <p>Understanding Parental Motivations and Decision-Making for Adolescent Girls' Participation in the Long-Acting Cabotegravir (CAB-LA) Trial – Insights from HPTN 084-1</p> <p>First-in-human evaluation of the safety, pharmacokinetics, and neutralization activity of PGDM1400-LS, a V2 glycan-specific HIV-1 broadly neutralizing antibody, infused intravenously or subcutaneously in people without HIV-1 (HVTN140/HPTN101 Part A)</p> <p>A first-in-human phase 1 trial of PGT121.414.LS administered alone and in combination with VRC07-523LS: safety, tolerability, pharmacokinetics, and neutralization activity (HVTN 136/HPTN 092)</p> <p>Enhancing Inclusivity: Examining the Global Impact of Cultural Competency on Clinical Trial Recruitment in HPTN – 10 Year Update</p>